Home Cart Sign in  
Chemical Structure| 1140964-99-3 Chemical Structure| 1140964-99-3

Structure of Stenoparib
CAS No.: 1140964-99-3

Chemical Structure| 1140964-99-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2 and enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors.

Synonyms: E7449; 2X-121; MGI25036

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Stenoparib

CAS No. :1140964-99-3
Formula : C18H15N5O
M.W : 317.34
SMILES Code : O=C1NNC2=C3C1=CC=CC3=NC(CN4CC5=C(C=CC=C5)C4)=N2
Synonyms :
E7449; 2X-121; MGI25036
MDL No. :MFCD28167842
InChI Key :JLFSBHQQXIAQEC-UHFFFAOYSA-N
Pubchem ID :135565981

Safety of Stenoparib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H372-H410
Precautionary Statements:P501-P273-P260-P270-P264-P280-P391-P314-P337+P313-P305+P351+P338-P301+P312+P330
Class:9
UN#:3077
Packing Group:

Related Pathways of Stenoparib

epigenetics
DNA

Isoform Comparison

Biological Activity

Target
  • PARP1

    PARP1, IC50:1 nM

  • PARP2

    PARP2, IC50:1.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
DLD-1 cells 10 μmol/L 24 h To evaluate the effect of E7449 on Wnt signaling, results showed increased axin2 protein levels. Oncotarget. 2015 Dec 1;6(38):41307-23.
SW480 cells 10 μmol/L 24 h To evaluate the effect of E7449 on Wnt signaling, results showed increased axin2 protein levels and decreased β-catenin levels. Oncotarget. 2015 Dec 1;6(38):41307-23.
DT40 cells 0.1-10 μmol/L 30 min To evaluate the role of E7449 in DNA damage repair, results showed increased PARP1 binding to chromatin. Oncotarget. 2015 Dec 1;6(38):41307-23.
LLC-MK2 rhesus macaque kidney cells 30 μM 120 hours Evaluate the inhibitory effect of Stenoparib on HCoV-NL63, showing a 69.3% reduction in plaquing efficiency and 95.8% reduction in viral copy number mBio. 2021 Jan 19;12(1):e03495-20.
Calu-3 human lung adenocarcinoma cells 60 μM 120 hours Evaluate the inhibitory effect of Stenoparib on SARS-CoV-2, showing nearly complete inhibition of plaque formation (94.0%) mBio. 2021 Jan 19;12(1):e03495-20.
Vero E6 monkey kidney cells 30 μM 48 hours Evaluate the inhibitory effect of Stenoparib on SARS-CoV-2, showing a significant 63.2% reduction in viral load mBio. 2021 Jan 19;12(1):e03495-20.
A549 cells 10 mol/L 48 hours E7449 significantly downregulated TNKS expression, inhibited proliferation, migration, and invasion of A549 cells, and induced early apoptosis. J Cell Mol Med. 2024 Jun;28(12):e18467.
A549L6 cells 5.753 µM (IC50) 96 hours Evaluate the inhibitory effect of E7449 on proliferation and migration of A549L6 cells Cancers (Basel). 2025 Feb 6;17(3):559.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice B16-F10 isograft model Orally 10, 30, 100 mg/kg Once daily for 7 days To evaluate the antitumor effect of E7449 in combination with TMZ, results showed significantly enhanced tumor growth inhibition. Oncotarget. 2015 Dec 1;6(38):41307-23.
BALB/c nude mice Subcutaneous xenograft model with A549 cells Gavage 100 mg/kg Once daily for 14 days E7449 significantly inhibited the growth of subcutaneous lung adenocarcinoma tumors and induced apoptosis by attenuating the Wnt signaling pathway. J Cell Mol Med. 2024 Jun;28(12):e18467.
BALB/c nude mice LUAD bone metastasis model Oral 40 mg/kg Once daily for 21 days Evaluate the inhibitory effect of E7449 on bone metastasis Cancers (Basel). 2025 Feb 6;17(3):559.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.15mL

0.63mL

0.32mL

15.76mL

3.15mL

1.58mL

31.51mL

6.30mL

3.15mL

References

 

Historical Records

Categories